ArticleFrontiers in cellular neuroscience2026
Compassionate-use of autologous, bone marrow-derived mesenchymal stromal cells in a chronic anoxic encephalopathy: a case report.
Article in Frontiers in cellular neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Severe hypoxic-ischemic brain injury may evolve into prolonged disorders of consciousness, for which disease-modifying interventions remain a challenge. Mesenchymal stromal/stem cells (MSCs) are being investigated in neurological disorders predominantly through immunomodulatory and trophic paracrine mechanisms rather than neuronal replacement. Methods: We describe a young adult medicine student with chronic post-anoxic encephalopathy managed under national regulatory oversight for compassionate use of an advanced cellular therapy. Autologous bone marrow-derived MSCs were harvested and expanded under GMP-oriented controls with extensive biosecurity and release testing. Quantitative EEG and source localization with low-resolution electromagnetic tomography (LORETA) were performed before transplantation and 4 months thereafter. Results: Four months after intrathecal administration, subtle but consistent behavioral changes were observed, including more synchronized affective responses, greater environmental engagement, and the first reproducible binary interaction via eye blinking. Retrospective review of available video documentation showed an increase in the Coma Recovery Scale-Revised (CRS-R) score from 8 before treatment to 11 after treatment, with one-point improvements in auditory function, visual function, and arousal. Modified Ashworth Scale spasticity scores improved by 1 in some muscle groups. No adverse events were registered. Longitudinal quantitative EEG demonstrated persistent global slowing compatible with severe diffuse injury, with qualitative emergence of faster activity, high alpha (10-12 Hz) and low beta (12-18 Hz) in bilateral fronto-temporal areas. LORETA current-density maps showed a more anterior distribution of estimated generators toward fronto-limbic regions. Discussion: This case illustrates the feasibility and short-term safety of regulated autologous MSC delivered intrathecally in chronic post-anoxic encephalopathy, while emphasizing that therapeutic efficacy cannot be inferred from a single uncontrolled observation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.